Incyte Corporation — Q2 2012 Form 10-Q
Reporting period: Three and six months ended June 30, 2012. Incyte is a biopharmaceutical company focused on oncology and inflammation; JAKAFI (ruxolitinib), approved in the U.S. for intermediate- or high-risk myelofibrosis, was its first marketed product. Amounts below are in U.S. dollars.
Financial performance and position
- Q2 revenue: $86.5 million, versus $16.8 million in Q2 2011. Product revenue was $29.7 million, contract revenue $56.7 million, and license and royalty revenue $0.1 million.
- Six-month revenue: $122.7 million, versus $48.8 million in the first half of 2011. Product revenue was $49.0 million; contract revenue was $73.5 million.
- Profit and loss: Q2 net income was $4.0 million ($0.03 per diluted share), compared with a $51.9 million net loss ($0.41 per share) a year earlier. First-half net loss was $41.4 million ($0.32 per share), versus $78.4 million ($0.63 per share) in 2011.
- Expenses: Q2 R&D was $51.6 million and SG&A was $19.7 million, compared with $46.0 million and $11.9 million, respectively, in Q2 2011. First-half R&D was $100.5 million and SG&A was $41.1 million. Q2 product cost was $16,000; management described cost of revenues as de minimis.
- Cash flow: First-half operating cash use was $45.7 million, versus $75.0 million in 2011. Investing cash use was $1.2 million; financing provided $31.3 million, primarily from stock-plan share issuance. Cash and cash equivalents declined $15.6 million to $257.6 million.
- Liquidity: Cash, cash equivalents and marketable securities totaled $261.8 million, excluding $9.5 million of restricted funds held for note interest payments. Current assets were $294.2 million and current liabilities $139.7 million at June 30.
- Debt and equity: Aggregate principal debt was $420 million: $400 million of 4.75% convertible senior notes due October 2015 and $20 million of Pfizer subordinated notes, with $10 million due in 2013 and $10 million in 2014. Carrying value of convertible notes was $328.3 million. Stockholders’ deficit was $217.2 million.
Material changes and drivers
- JAKAFI U.S. commercialization began after FDA approval in November 2011; the prior-year comparison had no product revenue. Q2 gross JAKAFI revenue recognized on patient prescriptions was $31.9 million, reduced by estimated rebates, discounts and other allowances to $29.7 million net.
- Q2 contract revenue included a $40 million Novartis regulatory milestone following the European Medicines Agency committee’s recommendation for EU approval of ruxolitinib. The milestone was recognized in Q2; the filing does not state that EU marketing authorization had been granted.
- Higher R&D reflected increased development headcount and clinical-trial activity. Higher SG&A reflected sales-force expansion and JAKAFI commercialization and marketing costs.
- First-half operating cash use improved primarily due to the Novartis milestone and JAKAFI product revenue. Stock-based compensation was $19.8 million for the first half, versus $14.1 million in 2011.
Outlook, risks and other notable items
- Management said available cash, cash equivalents and marketable securities were expected to fund capital needs for at least the next 12 months. It also warned that losses may continue and that profitability may never be achieved or sustained; no specific revenue or earnings guidance was provided.
- Management expected a Phase III rheumatoid-arthritis trial of baricitinib to begin later in 2012; baricitinib was also in a Phase IIb psoriasis trial. Ruxolitinib was in Phase III for polycythemia vera and Phase II for several other indications. These programs and timelines remained subject to clinical and regulatory uncertainty.
- Revenue recognition for JAKAFI used a sell-through approach: revenue was recorded when specialty pharmacies filled patient prescriptions, because Incyte lacked sufficient history to estimate returns. The company planned to move to sell-in recognition when it could estimate returns. Estimates for rebates, chargebacks, discounts and assistance programs could require later revenue adjustments.
- Revenue concentration was significant: one customer represented 62% of Q2 revenue and 55% of first-half revenue; three customers represented 66% of accounts receivable at June 30. The filing does not identify that customer in the stated concentration disclosure.
- Key risks include dependence on successful JAKAFI commercialization, reimbursement and pricing, specialty-pharmacy distribution, third-party manufacturing and single-source suppliers; clinical and regulatory setbacks; reliance on collaborators; and substantial debt service. The senior-note indenture restricts certain additional debt, liens and asset dispositions.
- Contractual obligations totaled $496.3 million, including principal and interest on debt and operating leases. Market-risk disclosure said a hypothetical immediate, uniform 10% rise in interest rates would not materially reduce investment fair value. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether JAKAFI prescription demand, net revenue and reimbursement support durable growth, and how sell-through estimates and customer concentration evolve.
- Whether the $40 million milestone is nonrecurring and how much future revenue depends on partner milestones, royalties and collaboration performance.
- Clinical progress and regulatory outcomes for ruxolitinib and baricitinib, including the anticipated baricitinib Phase III start and the status of EU authorization.
- Cash burn, commercialization and R&D spending, and the ability to meet debt obligations as the notes approach maturity.
- Manufacturing continuity, especially single-source supply exposure, and the potential impact of product-safety, regulatory, pricing or reimbursement developments.